1. Home
  2. PRFX vs NXTS Comparison

PRFX vs NXTS Comparison

Compare PRFX & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

N/A

Current Price

$0.90

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Logo Nexentis Technologies Inc. Common Stock

NXTS

Nexentis Technologies Inc. Common Stock

N/A

Current Price

$1.43

Market Cap

2.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
PRFX
NXTS
Founded
2007
2009
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PRFX
NXTS
Price
$0.90
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
54.2K
16.2K
Earning Date
03-26-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$263,445.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.58
$0.55
52 Week High
$5.39
$23.80

Technical Indicators

Market Signals
Indicator
PRFX
NXTS
Relative Strength Index (RSI) 34.44 35.88
Support Level $0.60 $1.43
Resistance Level $1.21 $2.08
Average True Range (ATR) 0.05 0.12
MACD -0.00 0.02
Stochastic Oscillator 6.72 6.02

Price Performance

Historical Comparison
PRFX
NXTS

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Share on Social Networks: